Orphan Drugs Nefecon, Maribavir & Copanlisib Among New EU Filings

US Filings For The Orphan Drugs Are Under Review

Marketing applications for two generic versions of the multiple sclerosis blockbuster, Tecfidera, are also under review by the European Medicines Agency.

European Medicines Agency HQ in Amsterdam
The EMA has begun reviewing a new batch of marketing applications • Source: Alamy

The European Medicines Agency has begun reviewing a number of new medicines for potential pan-EU marketing authorization, including three investigational orphan drugs –Nefecon (budesonide), maribavir and copanlisib, from Calliditas Therapeutics, Takeda Pharmaceutical and Bayer respectively.

The three rare disease drugs are among seven new products that the EMA added to its latest monthly list...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography